Quantitative Neuromuscular Monitoring Permits Early Diagnosis of Abnormal Butyrylcholinestrase: Two Case Studies Demonstrating Prevention of Awareness from Premature Awakening.

Administration of succinylcholine to patients with a variant in the butyrylcholinesterase (BChE) gene increases the risk of anesthesia emergence prior to recovery from neuromuscular blockade (NMB). Application of quantitative neuromuscular monitoring (NMM) can identify residual NMB. We present two patients with abnormal BChE gene variants. In the first case, quantitative monitoring was applied too late to prevent awareness, but allowed diagnosis and prevented admission to the intensive care unit. In the second case, monitoring was applied prior to NMB, which enabled early diagnosis and prevented premature awakening from anesthesia. These cases illustrate the importance of quantitative NMM, even in short cases and with short-acting depolarizing agents such as succinylcholine. The clinical implications of this report include a more consistent use of NMM to identify and manage patients with undiagnosed abnormal BChE and to prevent premature anesthesia emergence.

How do we improve blood product administration audit rates.

BACKGROUND: Failure to comply with institutional and national standards for blood product administration poses patient safety risks. Monitoring adherence to blood product administration policy is important for maintaining patient safety and ensuring regulatory agency compliance. STUDY DESIGN AND METHODS: This post-implementation quality improvement project evaluated an electronic paging system that was developed to facilitate perioperative blood product administration audits. RESULTS: Of the 57 audits conducted, 55 (96.5%) audits were fully completed. Anesthesia providers verified the patient name and medical record number (MRN) on the patient's armband with the product ID tag in 36.5% (n = 20) of audits. Anesthesia providers ensured the name and MRN on the armband matched the compatibility label on the blood product in 23% (n = 23) of audits. DISCUSSION: Ongoing surveillance of blood product administration practices is needed to monitor adherence to blood product administration policy, promote patient safety, and avoid imminent financial consequences from noncompliance to national regulatory standards.